274 related articles for article (PubMed ID: 25832652)
1. JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.
Schönberg K; Rudolph J; Vonnahme M; Parampalli Yajnanarayana S; Cornez I; Hejazi M; Manser AR; Uhrberg M; Verbeek W; Koschmieder S; Brümmendorf TH; Brossart P; Heine A; Wolf D
Cancer Res; 2015 Jun; 75(11):2187-99. PubMed ID: 25832652
[TBL] [Abstract][Full Text] [Related]
2. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
Vargas-Hernández A; Mace EM; Zimmerman O; Zerbe CS; Freeman AF; Rosenzweig S; Leiding JW; Torgerson T; Altman MC; Schussler E; Cunningham-Rundles C; Chinn IK; Carisey AF; Hanson IC; Rider NL; Holland SM; Orange JS; Forbes LR
J Allergy Clin Immunol; 2018 Jun; 141(6):2142-2155.e5. PubMed ID: 29111217
[TBL] [Abstract][Full Text] [Related]
4. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
5. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
[TBL] [Abstract][Full Text] [Related]
6. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
7. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
Mestre-Durán C; Martín-Cortázar C; García-Solís B; Pernas A; Pertíñez L; Galán V; Sisinni L; Clares-Villa L; Navarro-Zapata A; Al-Akioui K; Escudero A; Ferreras C; Pérez-Martínez A
Front Immunol; 2022; 13():1045316. PubMed ID: 36685552
[TBL] [Abstract][Full Text] [Related]
9. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
10. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Parampalli Yajnanarayana S; Stübig T; Cornez I; Alchalby H; Schönberg K; Rudolph J; Triviai I; Wolschke C; Heine A; Brossart P; Kröger N; Wolf D
Br J Haematol; 2015 Jun; 169(6):824-33. PubMed ID: 25824483
[TBL] [Abstract][Full Text] [Related]
11. Low-dose ruxolitinib shows effective in treating myelofibrosis.
Yang Y; Luo H; Zheng Y; Zou Z; Niu T; Jia Y; Zhu H; Liu T; Wu Y; Chang H; Ji J; Li J; Pan L
Ann Hematol; 2021 Jan; 100(1):135-141. PubMed ID: 33083863
[TBL] [Abstract][Full Text] [Related]
12. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
13. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
14. Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):990-992. PubMed ID: 29651917
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
16. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib: a new treatment option for myelofibrosis.
Ganetsky A
Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Sapre M; Tremblay D; Wilck E; James A; Leiter A; Coltoff A; Koshy AG; Kremyanskaya M; Hoffman R; Mascarenhas JO; Gallagher EJ
Sci Rep; 2019 Nov; 9(1):16609. PubMed ID: 31719581
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.
Cortés AA; Diaz RA; Hernández-Campo P; Gorrochategui J; Primo D; Robles A; Morales ML; Ballesteros J; Rapado I; Gallardo M; Linares M; Martínez-López J
Haematologica; 2019 May; 104(5):937-946. PubMed ID: 30545926
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
